Beam Therapeutics (BEAM) Stock Forecast & Price Target
Score
Beam Therapeutics Inc. price target
| BEAM | |
|---|---|
| Low | $39.00 |
| Average | $66.00 |
| High | $80.00 |
| Upside vs current price | +189.1% |
The average target of $66.00 is +189.1% versus the current BEAM price of $22.83.
Beam Therapeutics Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 12 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
15 analysts cover BEAM.
Beam Therapeutics Inc. EPS and revenue estimates
The estimate table for the Beam Therapeutics Inc. keeps 2026 EPS $-4.44, 2027 EPS $-4.82, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-4.44 | $51.24M |
| 2027 | $-4.82 | $62.27M |
Is Beam Therapeutics Inc. a buy or sell?
Of the 15 analysts covering Beam Therapeutics Inc., 13 rate it a buy (1 strong buy and 12 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The BEAM consensus label is Buy, beside 13 buy-side ratings and 0 sell-side ratings.
The average target of $66.00 implies +189.1% versus the current price of $22.83.
the Beam Therapeutics Inc. closes with 13 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Beam Therapeutics Inc. forecast
Analysts are far apart on BEAM. The published low is $39.00, the average is $66.00, and the high is $80.00.
From today's $22.83 print, the BEAM average target is +189.1% away.
Most of the BEAM coverage agrees: 13 of 15 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
BEAM targets have not moved much: $79.00 recently, $79.00 across the quarter.
Coverage of BEAM is broad at 15 analysts, and the average is a crowd rather than a single desk.
Beam Therapeutics Inc. forecast questions
What is the BEAM price target?
The published range for BEAM is $39.00 to $80.00, with an average of $66.00. That average is +189.1% versus the current price of $22.83.
Is Beam Therapeutics Inc. a buy or sell?
Of the 15 analysts covering Beam Therapeutics Inc., 13 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for BEAM is 13 on the buy side, 2 at hold, and 0 on the sell side.
What is the EPS estimate for Beam Therapeutics Inc.?
Analyst EPS estimates for Beam Therapeutics Inc.: 2026 $-4.44, 2027 $-4.82.
What is the revenue estimate for Beam Therapeutics Inc.?
Analyst revenue estimates for Beam Therapeutics Inc.: 2026 $51.24M, 2027 $62.27M.
How many analysts cover BEAM?
15 analysts cover BEAM. Their consensus on BEAM is Buy, across those 15.